The cancer diagnostics company BiBBInstruments AB (“BiBB or the “Company”) today announces that the European Patent Office (EPO) has finally approved two patent applications for EndoDrill®. The patents provide broad protection of the EndoDrill® system until 2038 and 2039, respectively.
The approvals relate to patent applications EP19780264.8 and EP18199230.6 from patent family 1 and follow previous Intention to Grants from the EPO announced in Q1 2023.
The cancer diagnostics company BiBBInstruments AB (“BiBB” or the “Company”) today reports that the first clinical study with EndoDrill® URO for muscle-invasive bladder cancer has been scientifically published in European Urology Open Science. The study shows that EndoDrill® URO safely can take treatment-based tissue samples earlier in the care chain in case of suspicion of deep-growing tumors in the urinary bladder. Läs mer
The cancer diagnostics company BiBBInstruments AB (“BiBB” or the “Company”), which develops and manufactures a new type of electric-driven endoscopic biopsy instrument, EndoDrill®, hereby provides a status update on the CE mark approval process of the product portfolio EndoDrill®. In summary, after discussions with BiBB’s notified body,
The cancer diagnostics company BiBBInstruments AB (“BiBB” or the “Company”), which develops and manufactures a new type of electric-driven endoscopic biopsy instrument, EndoDrill®, announces that the Company has now received a 510(k) market clearance from the US Food and Drug Administration (FDA) for EndoDrill® GI. The clearance means that BiBB can now market and sell EndoDrill®
Today, the cancer diagnostics company BiBBInstruments AB (“BiBB” or the “Company”) announces that the Company has received an additional Intention to Grant from the European Patent Office (“EPO”). The announcement means that the EPO intends to approve the Company’s first patent family in Europe for EndoDrill®, the world’s first CE-marked electric-driven endoscopic biopsy instrument. Läs mer
The cancer diagnostics company BiBBInstruments AB (“BiBB or the “Company”) announces that the Company has received an Intention to Grant from the European Patent Office (EPO). This means that EPO intends to approve the Company’s first patent application in Europe for EndoDrill®, the world’s first CE-marked electric-driven endoscopic biopsy instrument. A few additional formal steps will follow before a final notice of approval can be issued,
